FDA
FDA OKs label change allowing for re-administration of iDose TR
On January 28, 2026, FDA approved labeling change allowing for re-administration of iDose TR (travoprost intracameral implant) using a repeat treatment protocol.
Physicians may now re-administer additional doses of iDose TR as long as corneal health—measured by endothelial cell density—remains stable. Clinical trial data show that iDose TR maintains a strong long‑term corneal safety profile, with no clinically meaningful endothelial cell loss reported over three years in both phase 3 and phase 2b studies. In addition, findings from the iDose TR exchange study indicate that removing the initial implant and administering a second dose was safe and well‑tolerated, with the replacement implant demonstrating a favorable safety profile over 12 months.
When re-administering an iDose TR implant, the previous iDose TR should be removed after implantation of the new implant.
Sources:
iDose TR (travoprost intracameral implant) [package insert]. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218010s004lbl.pdf Revised January 2026. Accessed January 29, 2026.
Glaukos announces US FDA approval of NDA supplement allowing for re-administration of iDose® TR. [News release]. 2026. https://investors.glaukos.com/news/news-details/2026/Glaukos-Announces-US-FDA-Approval-of-NDA-Supplement-Allowing-for-Re-Administration-of-iDose-TR/default.aspx